Liebe Mitstreiter,
anbei Auszüge von der nationalen Versammlung der American Association for Cancer Research (AACR) zum Thema Antiangiogenese und Prostatakrebs. Nur den kleineren Teil habe ich übersetzt. Die gesamten Notizen zu diesem Teil des Kongresse, geschrieben von Jim Waldenfels, zum Schluß dieser Information.
Auszug aus Jim Waldenfels' Notizen -
Dr. Rakesh Jain, Harvard Medical School, informierte unsere Gruppe über das Schließen einer Wissenslücke bezüglich der Antiangiogenese und dem Wirkungsweg von Medikamenten im Patienten. Dr. Jain ist Kollege in Havard, von Dr. Folkman, dem "Vater" der Antiangiogenese.
Dr. Jain traf die überraschende Feststellung, daß es so scheint als ob die Antiangiogenese wirksam gegen Krebs ist, weil sie die Blutversorgung des Tumors verbessert und damit auch die Medikamentenzufuhr in den Tumor effizienter würde. Offensichtlich sind die Blutgefäße im Tumor unorganisiert/chaotisch. Dr. Jain zeigte hierzu beweisende Aufnahmen. Bei sorgfältiger Anwendung scheinen Antiangiogenese fördernde Medikamente die Blutgefäße neu zu sortieren und weniger aber stärkere Gefäße zu provozieren. Durch diesen Effekt könnten Medikamente in geringeren Dosen gleiche Wirkung erzielen. Dr. Jaine stellte ebenfalls fest, daß Tumorzellen agressiver sind in einem sauerstoffarmen Milieu, welches durch die Verbesserung der Blutversorgung durch antiangiogentisch wirkende Medikation theoretisch positiv beeinflußt würde. Weiterhin vermutete Dr. Jain, daß die Anwendung von Sauerstofftherapien wirksamer im Zusammenwirken mit antiangogentischen Medikamenten sein würden.
Originalnotizen von Jim Waldenfels -
The news about progress with anti-angiogenesis, discussed briefly earlier, was most encouraging. We learned that tumors cannot grow larger than a beebe without a blood supply. Until recently the news about anti-angiogenesis therapy was discouraging. Dr. Judah Folkman’s theory, published in 1971, just did not seem to be panning out in practice. There was no proof of effectiveness of anti-angiogenesis therapy for decades. However, during this time of great skepticism, in 2004 the first success in a clinical trial was published, and now, with the FDA approving anti-angiogenesis drugs at a rapid pace, the cancer community has become excited about this therapy. Lots of work is being done, with 130 clinical trials in progress involving 25 tumor types. When Dr. Folkman published his theory in 1971, there were two other publications on anti-angiogenesis. Through 2002 that total had risen to 16,804. Current research includes using anti-angiogenesis in an adjuvant role, in contrast to its previous use in late-stage disease. The company producing the anti-angiogenesis drug Avastin cannot hire people quickly enough to run the trials it would like. Clearly there is a need to monitor side effects, but if there is a problem, the therapy can be adjusted.
Dr. Jain made the surprising statement that it appears anti-angiogenesis drugs may work by making the tumor’s blood supply system work better, thereby increasing the blood supply, but also enabling more effective drug delivery to the tumor! It’s not as contradictory as it looks at first. Apparently the blood vessels in the tumor are disorganized and chaotic; Dr. Jain showed us photos that demonstrated this. With “judicious” use, the anti-angiogenesis drugs seem to winnow the vessels, leaving stronger but fewer vessels in the end. Dr. Jain used the analogy of a city with highly disorganized highways. The anti-angiogenesis drug is like an ngineering/construction team that replaces the old system with a modern, efficient system. With the more efficient blood vessel system in the tumor, drugs can be delivered at smaller doses and still be effective. He also noted that tumors are more aggressive if they are short of oxygen, a state known as hypoxia. A better blood supply can supply more oxygen, theoretically reducing hypoxia and thereby reducing aggressiveness, and he speculated that even hyperbaric treatment might be more effective in conjunction with anti-angiogenesis used to improve delivery of blood to the tumor. He also noted that radiation is more effective if you can reduce hypoxia. He concluded with a caution that anti-angiogenesis drugs alone will not work as they do not kill all the blood vessels.
anbei Auszüge von der nationalen Versammlung der American Association for Cancer Research (AACR) zum Thema Antiangiogenese und Prostatakrebs. Nur den kleineren Teil habe ich übersetzt. Die gesamten Notizen zu diesem Teil des Kongresse, geschrieben von Jim Waldenfels, zum Schluß dieser Information.
Auszug aus Jim Waldenfels' Notizen -
Dr. Rakesh Jain, Harvard Medical School, informierte unsere Gruppe über das Schließen einer Wissenslücke bezüglich der Antiangiogenese und dem Wirkungsweg von Medikamenten im Patienten. Dr. Jain ist Kollege in Havard, von Dr. Folkman, dem "Vater" der Antiangiogenese.
Dr. Jain traf die überraschende Feststellung, daß es so scheint als ob die Antiangiogenese wirksam gegen Krebs ist, weil sie die Blutversorgung des Tumors verbessert und damit auch die Medikamentenzufuhr in den Tumor effizienter würde. Offensichtlich sind die Blutgefäße im Tumor unorganisiert/chaotisch. Dr. Jain zeigte hierzu beweisende Aufnahmen. Bei sorgfältiger Anwendung scheinen Antiangiogenese fördernde Medikamente die Blutgefäße neu zu sortieren und weniger aber stärkere Gefäße zu provozieren. Durch diesen Effekt könnten Medikamente in geringeren Dosen gleiche Wirkung erzielen. Dr. Jaine stellte ebenfalls fest, daß Tumorzellen agressiver sind in einem sauerstoffarmen Milieu, welches durch die Verbesserung der Blutversorgung durch antiangiogentisch wirkende Medikation theoretisch positiv beeinflußt würde. Weiterhin vermutete Dr. Jain, daß die Anwendung von Sauerstofftherapien wirksamer im Zusammenwirken mit antiangogentischen Medikamenten sein würden.
Originalnotizen von Jim Waldenfels -
The news about progress with anti-angiogenesis, discussed briefly earlier, was most encouraging. We learned that tumors cannot grow larger than a beebe without a blood supply. Until recently the news about anti-angiogenesis therapy was discouraging. Dr. Judah Folkman’s theory, published in 1971, just did not seem to be panning out in practice. There was no proof of effectiveness of anti-angiogenesis therapy for decades. However, during this time of great skepticism, in 2004 the first success in a clinical trial was published, and now, with the FDA approving anti-angiogenesis drugs at a rapid pace, the cancer community has become excited about this therapy. Lots of work is being done, with 130 clinical trials in progress involving 25 tumor types. When Dr. Folkman published his theory in 1971, there were two other publications on anti-angiogenesis. Through 2002 that total had risen to 16,804. Current research includes using anti-angiogenesis in an adjuvant role, in contrast to its previous use in late-stage disease. The company producing the anti-angiogenesis drug Avastin cannot hire people quickly enough to run the trials it would like. Clearly there is a need to monitor side effects, but if there is a problem, the therapy can be adjusted.
Dr. Jain made the surprising statement that it appears anti-angiogenesis drugs may work by making the tumor’s blood supply system work better, thereby increasing the blood supply, but also enabling more effective drug delivery to the tumor! It’s not as contradictory as it looks at first. Apparently the blood vessels in the tumor are disorganized and chaotic; Dr. Jain showed us photos that demonstrated this. With “judicious” use, the anti-angiogenesis drugs seem to winnow the vessels, leaving stronger but fewer vessels in the end. Dr. Jain used the analogy of a city with highly disorganized highways. The anti-angiogenesis drug is like an ngineering/construction team that replaces the old system with a modern, efficient system. With the more efficient blood vessel system in the tumor, drugs can be delivered at smaller doses and still be effective. He also noted that tumors are more aggressive if they are short of oxygen, a state known as hypoxia. A better blood supply can supply more oxygen, theoretically reducing hypoxia and thereby reducing aggressiveness, and he speculated that even hyperbaric treatment might be more effective in conjunction with anti-angiogenesis used to improve delivery of blood to the tumor. He also noted that radiation is more effective if you can reduce hypoxia. He concluded with a caution that anti-angiogenesis drugs alone will not work as they do not kill all the blood vessels.
Kommentar